Frontotemporal dementia

9 trials 4 recruiting MedDRA PT
9 Registered trials
4 Recruiting
9 Unique sponsors
7 Unique IMPs
8 Commercial trials
Drug classes (ATC)
— ATC code not specified 8
H Endocrinology (ATC H) 1
L Oncology (ATC L) 1
N Neurology/Psychiatry (ATC N) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 3 substances
Corticosteroid 2 substances
mTOR inhibitor 1 substance
Monoclonal antibody (neural) 1 substance
Phase III: 1 Phase I/II: 2 Phase I: 4 Phase I (Other): 1 Phase I (First in Human): 2

Filter these 9 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 9 trials

Phase III

1 trial
  • Alector LLC Academic
    LATOZINEMAB
    2023-506873-36-00 9 countries 2020 n=79 Orphan
    Ended

Phase I/II

2 trials
  • Prevail Therapeutics Inc. Commercial
    ADENO-ASSOCIATED VIRAL VECTOR SEROTYPE 9 EXPRESSING CODON-OPTIMIZED HUMAN GRN GENE; METHYLPREDNISOLONE; PREDNISONE; SIROLIMUS
    2022-502942-29-01 2 countries 2026 n=13 Orphan
    Ended
  • ZRO Imaging AB Commercial
    IMP not specified
    2025-522826-11-00 1 country 2025 n=64
    Recruiting

Phase I

4 trials
  • AC Immune S.A. Commercial
    IMP not specified
    2024-513097-21-00 1 country 2024 n=45
    Recruiting
  • Insusense ApS Commercial
    IMP not specified
    2023-505847-38-00 1 country 2023 n=78
    Ended
  • Molefy Pharma S.L. Commercial
    IMP not specified
    2025-524480-21-00 1 country 2026 n=72
    Recruiting
  • Insusense ApS Academic
    IMP not specified
    2023-505847-38-00 1 country 2023 n=78
    Ended

Phase I (Other)

1 trial
  • Vesper Bio ApS Commercial
    IMP not specified
    2024-513258-31-00 1 country 2024 n=3
    Ended

Phase I (First in Human)

2 trials
  • Aviadobio Limited Commercial
    AVB-101
    2023-509444-10-00 6 countries 2024 n=16 Orphan
    Recruiting
  • Denali Therapeutics Inc. Commercial
    DNL593
    2023-508697-28-00 7 countries 2024 n=55
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Insusense ApS Commercial 2 Phase I 0
AC Immune S.A. Commercial 1 Phase I 1
Molefy Pharma S.L. Commercial 1 Phase I 1
Vesper Bio ApS Commercial 1 Phase I (Other) 0
Aviadobio Limited Commercial 1 Phase I (First in Human) 1
Denali Therapeutics Inc. Commercial 1 Phase I (First in Human) 0
Prevail Therapeutics Inc. Commercial 1 Phase I/II 0
ZRO Imaging AB Commercial 1 Phase I/II 1
Alector LLC Academic 1 Phase III 0
New trials by year
2020
1
2023
2
2024
4
2025
1
2026
2
← All indication landscapes